Time-dependent effects of Klebsiella pneumoniae endotoxin on the pharmacokinetics of chlorzoxazone and its main metabolite, 6- hydroxychlorzoxazone, in rats: Restoration of the parameters in 96 hour in KPLPS rats to control levels

Biopharmaceutics and Drug Disposition

Volumn 30, Issue 8, 2009, Pages 485-493

  Jung, Hye Y ^a,c   Kang, Hee E ^a   Choi, Young H ^a   Kim, So H ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Gangneung Wonju National University   (South Korea)

^c Dong A Pharmaceutical Company   (South Korea)

Author keywords

Chlorzoxazone and 6 hydroxychlorzoxazone; Hepatic Cyp2e1; Klebsiella pneumoniae; Pharmacokinetics; Rats

Indexed keywords

6 HYDROXYCHLORZOXAZONE; CHLORZOXAZONE; CYTOCHROME P450 2E1; ENDOTOXIN; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG PROTEIN BINDING; ENZYME ANALYSIS; ENZYME KINETICS; KLEBSIELLA PNEUMONIAE; MALE; NONHUMAN; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ENDOTOXINS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, ACUTE; KLEBSIELLA PNEUMONIAE; LIPOPOLYSACCHARIDES; MALE; MICROSOMES, LIVER; MUSCLE RELAXANTS, CENTRAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 70549107983     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.685     Document Type: Article

References (32)

1. Conney AH, Burns JJ. Physiological disposition and metabolic fate of chlorzoxazone (Paraflex) in man. J Pharmacol Exp Ther 1960; 128: 340-343.
2. Ahn CY, Kim EJ, Lee IC, et al. Effect of glucose on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. J Pharm Sci 2003; 92: 1604-1613. (Pubitemid 36929680)
3. Ahn CY, Bae SK, Jung YS, et al. Pharmacokinetic parameters of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, after intravenous and oral administration of chlorzoxazone to liver cirrhotic rats with diabetes mellitus. Drug Metab Dispos 2008; 36: 1233-1241.
4. Peter R, Bocker R, Beaune PH, et al. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 2E1. Chem Res Toxicol 1990; 3: 566-573.
5. Rockich K, Blouin R. Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats. Drug Metab Dispos 1999; 27: 1074-1077. (Pubitemid 29409645)
6. Court MH, von Moltke LL, Shader RI, et al. Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos 1997; 18: 213-226.
7. Ghiselli R, Cirioni O, Giacometti A, et al. The cathelicidin-derived tritrpticin enhances the efficacy of ertapenem in experimental rat models of septic shock. Shock 2006; 26: 195-200. (Pubitemid 44162507)
8. Nadai M, Sekido T, Matsuda I, et al. Time-dependent effects of Klebsiella pneumoniae endotoxin on hepatic drug-metabolizing enzyme activity in rats. J Pharm Pharmacol 1998; 50: 871-879. (Pubitemid 28421154)
9. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
10. Kim SG, Kim EJ, Kim YG, et al. Expression of cytochrome P-450 s and glutathione S-transferases in the rat liver during water deprivation: effects of glucose supplementation. J Appl Toxicol 2001; 21: 123-129.
11. Duggleby RG. Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol 1995; 249: 61-90.
12. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6: 165-175. (Pubitemid 8384279)
13. Akaike H. An information criterion (AIC). Math Sci 1976; 14: 5-9.
14. Boudinot FD, Jusko WJ. Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 1984; 73: 774-780. (Pubitemid 14122792)
15. Øie S, Guentert TW. Comparison of equilibrium time in dialysis experiments using spiked plasma or spiked buffer. J Pharm Sci 1982; 71: 127-128.
16. Frye RF, Stiff DD. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. J Chromatogr B 1996; 686: 291-296. (Pubitemid 26402969)
17. Liu PT, Ioannides C, Shavila J, et al. Effects of ether anaesthesia and fasting on various cytochromes P450 of rat liver and kidney. Biochem Pharmacol 1993; 45: 871-877. (Pubitemid 23071437)
18. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-546.
19. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. Marcel-Dekker: New York, 1982.
20. Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 2006; 46: 123-149.
21. Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 2001; 92: 147-163.
22. Yang KH, Lee MG. Effects of lipopolysaccharide on pharmacokinetics of drugs. J Toxicol Pub Health 2007; 23: 289-299.
23. Baek HW, Bae SK, Lee MG, et al. Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation. J Pharm Sci 2006; 95: 2452-2462.
24. Nadai M, Hasegawa T, Kato K, et al. The disposition and renal handling of enprofylline in endotoxemic rats by bacterial lipopolysaccharide (LPS). Drug Metab Dispos 1993; 21: 611-616. (Pubitemid 23221755)
25. Saitoh T, Kokue E, Shimoda M. The impact of acute phase response on the plasma clearance of antipyrine, theophylline, phenytoin and nifedipine in rabbits. J Vet Pharmacol Ther 2000; 23: 153-158. (Pubitemid 30826958)
26. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002; 41: 1135-1151. (Pubitemid 35398690)
27. Carriere V, Goasduff T, Ratanasavanh D, et al. Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol 1993; 6: 852-857. (Pubitemid 23351209)
28. Yamazaki H, Guo Z, Guengerich FP. Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation. Drug Metab Dispos 1995; 23: 438-440.
29. Ono S, Hatanaka T, Hotta H, et al. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 1995; 5: 143-150.
30. Shimada T, Tsumura F, Yamazaki H. Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos 1999; 27: 1274-1280.
31. Gorski JC, Jones DR, Wrighton SA, et al. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 1997; 27: 243-256.
32. Ueyama J, Nadai M, Kanazawa H, et al. Endotoxin from various gram-negative bacteria has differential effects on function of hepatic cytochrome P450 and drug transporters. Eur J Pharmacol 2005; 510: 127-134. (Pubitemid 40312398)